VolitionRX
150 Orchard Road
Orchard Plaza 08-02
Singapore
238841
Website: http://www.volitionrx.com/
Email: info@volitionrx.com
267 articles about VolitionRX
-
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
3/20/2024
VolitionRx Limited has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd, a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.
-
Volition appoints Dr Andrew Retter as Chief Medical Officer
3/19/2024
VolitionRx Limited, a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
-
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
2/2/2024
VolitionRx Limited, a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
-
Volition Issues Business Review 2023
1/4/2024
VolitionRx Limited, a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
-
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
12/5/2023
VolitionRx Limited, a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million in financing from Wallonie Entreprendre S.A. in Belgium.
-
Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society
11/17/2023
VolitionRx Limited, a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.
-
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
11/14/2023
VolitionRx Limited announced financial results and a business update for the third quarter ended September 30, 2023. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results.
-
Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland
11/6/2023
VolitionRx Limited, a multi-national epigenetics company, and Veterinary Pathology Group, a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
-
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
10/23/2023
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology.
-
Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock
10/19/2023
VolitionRx Limited announces the publication of a clinical paper1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.
-
US Ambassador Adler visits Belgian Volition
10/18/2023
VolitionRx Limited, a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium.
-
Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis
10/13/2023
VolitionRx Limited, a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader roundtable on sepsis management.
-
Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar
10/2/2023
VolitionRx Limited, a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21st at ESMO 2023, the annual congress of the European Society for Medical Oncology.
-
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters
6/23/2023
VolitionRx Limited announced that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by Volition.
-
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock
6/5/2023
VolitionRx Limited, a multi-national epigenetics company, announced the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by Volition.
-
VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock
6/1/2023
VolitionRx Limited, a multi-national epigenetics company, announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share.
-
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock - May 31, 2023
5/31/2023
VolitionRx Limited, a multi-national epigenetics company, announced that it has commenced an underwritten public offering of shares of its common stock.
-
Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring
5/11/2023
VolitionRx Limited, a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers.
-
VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update
5/5/2023
VolitionRx Limited announced it will host a conference call on Thursday May 11 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2023, in addition to providing a business update.
-
VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.
4/26/2023
VolitionRx Limited, a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format on Thursday, May 11, 2023, at 2 p.m. U.S. Eastern Time.